MarketScreener Homepage > Equities > Nyse > Abbott Laboratories ABT

Report

Delayed Nyse - 01/15 04:10:00 pm
111.3	USD		+1.15%

01/15

ABBOTT LABORATORIES : To launch the neurosphere mypath digital health app designed to track and report pain relief in chronic pain patients with physicians prior to device implant

01/14

ABBOTT : to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant

01/14

ABBOTT LABORATORIES : Ex-dividend day for

Summary

Quotes 5-day view Delayed Quote.

Delayed Nyse

01/11/2021	01/12/2021	01/13/2021	01/14/2021	01/15/2021	Date
110.84(c)	108.84(c)	112.15(c)	110.04(c)	111.3(c)	Last
3 177 736	5 777 386	6 047 106	4 391 349	4 459 430	Volume
-0.69%	-1.80%	+3.04%	-1.88%	+1.15%	Change

More quotes

Financials (USD)

Sales 2020	33 853 M - -
Net income 2020	4 415 M - -
Net Debt 2020	11 794 M - -
P/E ratio 2020	45,4x
Yield 2020	1,29%

Sales 2021	38 321 M - -
Net income 2021	5 807 M - -
Net Debt 2021	8 819 M - -
P/E ratio 2021	35,1x
Yield 2021	1,41%

Capitalization	191 B 191 B -
EV / Sales 2020	5,98x
EV / Sales 2021	5,21x
Nbr of Employees	107 000
Free-Float	88,9%

More Financials

Company

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products,...

Sector

Medical Equipment, Supplies & Distribution

Calendar

01/27

Earnings Release

More about the company

Notations Surperformance© of Abbott Laboratories

Trading Rating :

Investor Rating :

More Ratings

All news about ABBOTT LABORATORIES

01/15	ABBOTT LABORATORIES : To launch the neurosphere mypath digital health app design..	AQ
01/14	ABBOTT : to Launch the NeuroSphere™ myPath™ Digital Health App Desig..	PR
01/14	ABBOTT LABORATORIES : Ex-dividend day for	FA
01/13	ABBOTT LABORATORIES : Announces fulfillment of federal government purchase of 15..	AQ
01/12	ABBOTT LABORATORIES : Fulfills US Government's Order of 150 Million BinaxNOW COV..	MT
01/12	ABBOTT : Announces Fulfillment of Federal Government Purchase of 150 Million Bin..	PR
01/11	ABBOTT LABORATORIES : Receives FDA 510(k) Clearance for Rapid Handheld Blood Tes..	MT
01/11	ABBOTT : Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test f..	PR
01/06	ABBOTT : Hosts Conference Call for Fourth-Quarter Earnings	PR
2020	ABBOTT LABORATORIES : - as vaccines roll out, americans see covid-19 testing as ..	AQ
2020	ABBOTT LABORATORIES : As Vaccines Roll Out, Americans See COVID-19 Testing as Im..	PR
2020	ABBOTT LABORATORIES : To present at j.p. morgan healthcare conference	AQ
2020	ROCHE : EU Signs $122 Million Deal for COVID-19 Rapid Antigen Tests From Abbott,..	MT
2020	ABBOTT : to Present at J.P. Morgan Healthcare Conference	PR
2020	ABBOTT LABORATORIES : Wins FDA Approval to Update Labeling on HeartMate 3 Heart ..	MT

More news

News in other languages on ABBOTT LABORATORIES

2020	Des sorcières, des dragons et des pirates
2020	AVIS D'ANALYSTES DU JOUR : ABB, Delta Plus, EDP, Galapagos, HelloFresh, Sika, Ve..
2020	CORONAVIRUS : Mepha distribue en Suisse le test rapide d'Abbott
2020	Generikafirma Mepha holt weiteren Covid-19-Schnelltest in die Schweiz
2020	AVIS D'ANALYSTES DU JOUR : Adidas, Chargeurs, Daimler, EDF, Ipsen, L'Oréal, SAP,..

More news

Analyst Recommendations on ABBOTT LABORATORIES

2020	ABBOTT LABORATORIES : Morgan Stanley Adjusts Abbott Laboratories PT to $126 From..	MT
2020	ABBOTT LABORATORIES : Goldman Sachs Adjusts Abbott Laboratories PT to $111 From ..	MT
2020	Morgan Stanley Adjusts Abbott Laboratories PT to $121 From $117, Maintains Ov..	MT

More recommendations

Provided by Scoopnest.com

Analysis

United to give travelers free COVID-19 tests on select Newark-London flights

More Must read

Chart ABBOTT LABORATORIES

Duration : Period :

Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener

Full-screen chart

Technical analysis trends ABBOTT LABORATORIES

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	23
Average target price	120,22 $
Last Close Price	111,30 $
Spread / Highest target	21,3%
Spread / Average Target	8,02%
Spread / Lowest Target	-26,3%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Robert B. Ford	President, CEO, Chief Operating Officer & Director
Miles D. White	Executive Chairman
Robert E. Funck	Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin	Independent Director
Samuel C. Scott	Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ABBOTT LABORATORIES	1.65%	190 701



MEDTRONIC PLC	-0.28%	157 229
BECTON, DICKINSON AND COMPANY	4.60%	76 127
HOYA CORPORATION	-2.24%	50 041
ALIGN TECHNOLOGY, INC.	6.15%	44 726
BAXTER INTERNATIONAL INC.	-0.25%	40 886

More Results